In the SYNERGY-NASH phase 2 trial, tirzepatide significantly reduced MASH biomarkers (AST/ALT, keratin-18 M30, and procollagen III) and c-reactive protein in diabetic patients. Here, CRP is linked to metabolic dysfunction-associated steatohepatitis.